abiraterone has been researched along with thiohydantoins in 11 studies
| Studies (abiraterone) | Trials (abiraterone) | Recent Studies (post-2010) (abiraterone) | Studies (thiohydantoins) | Trials (thiohydantoins) | Recent Studies (post-2010) (thiohydantoins) |
|---|---|---|---|---|---|
| 942 | 97 | 854 | 454 | 45 | 250 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 5 (45.45) | 2.80 |
| Authors | Studies |
|---|---|
| Courtney, KD; Taplin, ME | 1 |
| Kim, W; Ryan, CJ | 1 |
| Evans, CP; Isaacs, WB; Karantanos, T; Montironi, R; Thompson, TC; Tombal, B | 1 |
| Bambury, RM; Rathkopf, DE | 1 |
| Azoitei, A; Cronauer, MV; Godau, B; Hoda, MR; Merseburger, AS; Schmid, E | 1 |
| Buonerba, C; Di Lorenzo, G; Fizazi, K; Pagliuca, M | 1 |
| Autorino, R; Castellan, P; Cindolo, L; Di Nicola, M; Marchioni, M; Novara, G; Paul, AK; Primiceri, G; Schips, L; Veccia, A | 1 |
| Hadaschik, B; Hess, J; Hess-Busch, Y | 1 |
| Condon, B; Liskaser, G; Murphy, DG; Thangasamy, IA | 1 |
| Arranz, JA; Castro, E; Climent, MA; Gallardo, E; González Del Alba, A; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Méndez-Vidal, MJ; Vazquez, S | 1 |
| Bradic, B; Chi, KN; De Meulder, M; Espina, BM; Francis, P; Graff, JN; Hayreh, V; Hazra, A; Lattouf, JB; Mamidi, RNVS; Posadas, EM; Rezazadeh Kalebasty, A; Saad, F; Shore, ND; Yu, A; Zhu, E | 1 |
7 review(s) available for abiraterone and thiohydantoins
| Article | Year |
|---|---|
The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
Topics: Androgen Antagonists; Androgens; Androstadienes; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Benzimidazoles; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Steroid 17-alpha-Hydroxylase; Thiohydantoins | 2012 |
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Thiohydantoins | 2012 |
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Topics: Androgen Antagonists; Androstenes; Animals; Antineoplastic Agents, Hormonal; Benzamides; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Thiohydantoins | 2015 |
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
Topics: Androgen Receptor Antagonists; Androstadienes; Androstenes; Benzamides; Benzimidazoles; Humans; Male; Naphthalenes; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Receptors, Androgen; Thiohydantoins; Triazoles | 2016 |
C-terminally truncated constitutively active androgen receptor variants and their biologic and clinical significance in castration-resistant prostate cancer.
Topics: Alternative Splicing; Androgens; Androstenes; Androstenols; Animals; Benzamides; Biomarkers, Tumor; Codon, Terminator; Disease Progression; Epithelial-Mesenchymal Transition; Genetic Variation; Genome, Human; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Domains; Signal Transduction; Thiohydantoins; Transcription Factors | 2017 |
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Retrospective Studies; Taxoids; Thiohydantoins; Tissue Extracts | 2019 |
M0CRPC overview of management options.
Topics: Androstenes; Benzamides; Clinical Trials as Topic; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyrazoles; Thiohydantoins | 2021 |
1 trial(s) available for abiraterone and thiohydantoins
| Article | Year |
|---|---|
Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE).
Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Indazoles; Male; Middle Aged; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thiohydantoins | 2021 |
3 other study(ies) available for abiraterone and thiohydantoins
| Article | Year |
|---|---|
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Network Meta-Analysis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Thiohydantoins | 2020 |
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.
Topics: Administration, Oral; Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins | 2020 |
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Docetaxel; Genes, BRCA1; Genes, BRCA2; Genetic Testing; Humans; Male; Medical Oncology; Nitriles; Orchiectomy; Phenylthiohydantoin; Phthalazines; Piperazines; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic; Societies, Medical; Spain; Thiohydantoins | 2021 |